Vertex ended a closely watched effort to develop a therapy for liver disease, a setback in the biotech’s quest to broaden its offerings beyond cystic fibrosis drugs. The shares fell as much 15 percent after US markets closed Thursday.
from The Boston Globe https://ift.tt/3xcBhMP
Angelica LaVito
Vertex ended a closely watched effort to develop a therapy for liver disease, a setback in the biotech’s quest to broaden its offerings beyond cystic fibrosis drugs. The shares fell as much 15 percent after US markets closed Thursday.
https://ift.tt/35826Wv June 10, 2021 at 11:49PM
ليست هناك تعليقات:
إرسال تعليق